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Most cases of pulmonary arterial hypertension (PAH) are not idiopathic, but rather are attributable to
other disorders. This fact has become increasingly apparent following the recent establishment of
centralised PAH registries in several countries. Yet, this ‘‘secondary’’ PAH has been the subject of even less
research than idiopathic PAH, itself an orphan disease par excellence. Secondary PAH is heterogeneous:
prognosis and response to vasodilator therapy differs substantially between various forms of secondary
PAH, partly as a function of underlying pathophysiology, and cannot simply be extrapolated from data
derived from idiopathic PAH.
This article reviews the commonest secondary causes of PAH, focusing on epidemiology, risk factors,
clinical presentation, treatment options, prognosis, and the role of screening. PAH secondary to chronic
hypoxia, congenital heart disease, connective tissue disorders, liver disease, appetite suppressants and
stimulants, and HIV infection are all considered. Strengths and limitations of available screening tests for
PAH are discussed.
 2010 Elsevier Ltd. All rights reserved.Educational aims
 To review the pathophysiology and clinical features of the
commonest causes of secondary pulmonary arterial hyper-
tension (PAH).
 To review the evidence for efﬁcacy of the available treatment
modalities for PAH, when applied to secondary PAH.
 To understand the strengths and limitations of invasive and
noninvasive screening tests for PAH.
 To understand with which frequency and for which conditions
screening is recommended.
 To develop an understanding of prognosis of the various forms
of secondary PAH.1. Introduction
Pulmonary arterial hypertension (PAH) is deﬁned as a resting
mean pulmonary artery pressure (PAP) 25 mmHg, with normal
left atrial pressure. The incidence of PAH has been estimated at 15
cases per million, of which two thirds are ‘secondary’ PAH.1 Prev-
alence estimates for the various types of secondary PAH have
frequently been made on the basis of echocardiographic studies.þ64 9 6310712.
sher).
c.nz.Echocardiography is probably oversensitive for the diagnosis of
PAH,2,3 and right heart catheterisation (RHC) remains the gold
standard. The recent establishment of national registries of RHC-
conﬁrmed PAH in France and the United Kingdom are allowing
more accurate epidemiologic and prognostic information about
secondary PAH to come to light.1,4
The World Symposium on Pulmonary Hypertension (Venice,
2003) divides PH into ﬁve pathophysiological categories.5 Our review
focuses on secondary causes of pulmonary arterial hypertension
(category 1), including collagen vascular diseases, HIV infection and
anorexigen use. We also review PH related to chronic hypoxia (cate-
gory 2), and some miscellaneous conditions including sarcoidosis. In
the interests of space and brevity, pulmonary venous hypertension
and chronic thromboembolic disease are not reviewed.
2. Diagnostic tests
2.1. Echocardiography
Echocardiography is the test most frequently used to investigate
for suspected PAH. It is noninvasive, and is usually more readily
available than RHC. However, it is probably oversensitive for PAH2,3
and cannot distinguish between arterial and venous hypertension.
At present echocardiography is the best noninvasive test for
diagnosis of PAH, but echocardiographic ﬁndings (positive or
negative) need to be interpreted in combination with clinical clues
such as disproportionately poor exercise capacity, low transfer
coefﬁcient (DLCO) or clinical right heart failure.
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A DLCO that is lowered out of proportion to the degree of lung
disease is widely recognised as suggestive of PAH.6 This pattern can
also occur in mixed obstructive and restrictive lung disease. A
reduced DLCO has been associated with increased risk of PAH in
idiopathic pulmonary ﬁbrosis (IPF),7 systemic sclerosis (SSc)8 and
sarcoidosis.9
Current British Thoracic Society guidelines recommend annual
pulmonary function tests (PFTs) in SSc, proceeding to echocardi-
ography if the DLCO is declining or is disproportionately impaired.6
In ILD, consideration of PAH is also recommended where there is
a disproportionate reduction in DLCO.
2.3. Six minute walk test
The six minute walk test (6MWT) provides both useful prog-
nostic information and an objective baseline measure of functional
limitation which can then be followed to observe its response to
therapeutic interventions. Parameters derived from the 6MWT
have been commonly used to provide endpoints in therapeutic
trials in PAH. Though development of secondary PAH is known to
lower six minute walk distance (6MWD),10–12 the role of the 6MWT
in diagnosing PAH remains largely uninvestigated. A study in
sarcoidosis reported that oxygen saturation< 90% on 6MWT pre-
dicted PAH more accurately than 6MWD, and advocated using
a combination of 6MWTand echocardiography to screen for PAH in
this patient group.9 6MWT may be impractical as a diagnostic test
in those PAH-associated conditions that are marked by musculo-
skeletal disability or poor peripheral perfusion, such as
scleroderma.13
3. Pulmonary hypertension as a complication of hypoxaemia
3.1. Chronic obstructive pulmonary disease (COPD)
Among patients with COPD, mild PAH is common14 and corre-
lates with decline in FEV1. However a subpopulation of patients
have PAH disproportionate to the severity of airﬂow obstruc-
tion.14,15 Postulated mechanisms include emphysematous
destruction of the pulmonary vascular bed, hyperviscosity, in situ
thrombosis, and vascular remodelling due to hypoxic vasocon-
striction or chronic inﬂammation.16
COPDaccounted for 0.8%of cases of PAH in a retrospective studyat
a PAH referral centre.17 Among patients with COPD referred for lung
transplant, 7.4% had disproportionate PAH.14 Among 998 patients
with COPD who underwent RHC, only 2.7% had pulmonary artery
pressure (PAP)> 40 mmHg, and only 1.1% had PAHwith COPD as the
only identiﬁable cause.15 PAH of any degree is an adverse prognostic
indicator in COPD,18 possibly because it usually reﬂects more
advanced lung disease.
Echocardiography is relatively insensitive for COPD-associated
PAH, due probably to the increased distance that ultrasound
waves must penetrate. In a group of patients with advanced lung
disease (mostly COPD), echocardiography could only estimate right
ventricular systolic pressure (RVSP) in 44% of cases, and this
modality misclassiﬁed 48% of patients as having PAH.19 As echo-
cardiography cannot rule PAH-COPD in or out, clinicians must
consider other clues such as disproportionate impairment of DLCO,
6MWD, or clinical right heart function.
Some researchers have studied the role of exhaled biomarkers in
diagnosis of PAH complicating COPD. Levels of endothelin-1 (ET-1)
in exhaled breath condensate and plasma were increased, and
levels of exhaled nitric oxide reduced, in patients with PAH-COPD
compared to other patients with COPD and healthy controls.Moreover, ET-1 levels correlated with PAP and inversely correlated
with FEV1.
20
There are few studies of treatment of PAH-COPD. Long term
nifedipine was not beneﬁcial.21 Pulmonary vasodilators may
worsen hypoxaemia by counteracting hypoxic vasoconstriction and
diverting blood ﬂow to poorly ventilated areas of lung, as reported
in a recent observational study.22 Inhalational delivery may avoid
this problem23: indeed, an randomised trial of 3 months of inhaled
nitric oxide showed haemodynamic improvements in severe
COPD.24
A case of favourable response to bosentan has been reported25;
however bosentan showed no beneﬁcial effects and worsened gas
exchange in an randomised trial among patients with severe
COPD.26 Long-term sildenaﬁl was not associated with any
improvement in haemodynamics or 6MWD in a cohort of 5
patients.27 For the time being, use of pulmonary vasodilators in
PAH-COPD should be avoided outside the context of clinical trials.283.2. Sleep disordered breathing
Sleep disordered breathing (SDB) encompasses a variety of
disorders including obstructive and central sleep apnoea, and
nocturnal alveolar hypoventilation due to obesity (obesity hypo-
ventilation syndrome) or other mechanical respiratory abnormal-
ities. True PAH in the setting of SDB is presumed to be caused by
hypoxic vasoconstriction. In addition, a high proportion of patients
with obstructive sleep apnoea (OSA) have abnormal left ventricular
ﬁlling, which may cause pulmonary venous hypertension.29
Prevalence estimates of PAH in OSA range between 17–53%.30–33
Most PAH attributed to OSA appears to bemild: a systematic review
found that the mPAP was <30 mmHg in all published studies.34
There are few reported estimates of SDB prevalence in PAH: one
small study found that nocturnal oxygen desaturation was very
common in idiopathic pulmonary arterial hypertension (IPAH),
whereas apnoeas and hypopnoeas were rare.35 Desaturation was
associated with diurnal hypoxaemia, desaturation with exercise,
and higher A-a gradients. Diurnal hypoxaemia and nocturnal
desaturation have been identiﬁed as risk factors for PAH in SDB in
a number of studies.30,31,36,37 Body mass index (BMI) is a risk factor
in some studies30,31,36 but not others.32,37 Apnoea–hypopnoea
index is a risk factor in a minority of studies.29,31,32
Successful treatment of OSA with CPAP usually lowers
PAP,29,36,38 even in severe cases.39 No published studies have
examined clinical outcomes in the treatment of PAH-SDB.
The American College of Chest Physicians currently recom-
mends that ‘‘assessment for SDB’’ is undertaken in all patients with
PAH.34 Polysomnography is recommended only if there is clinical
suspicion of OSA however. Conversely, screening for PAH in patients
with OSA is not recommended.3.3. Idiopathic pulmonary ﬁbrosis (IPF)
Information in the prevalence of PAH in IPF is scant, with
reported estimates of up to 84% in echocardiographic studies,40,41
but lower prevalences of 8.1% using RHC.42 PAH also correlates
poorly with lung function test results,7 suggesting that it is not
simply a consequence of severe lung disease.
PAH appears to worsen prognosis in IPF, with a recent retro-
spective study reporting 1 year mortality of 61.2%, versus 19.9% in
patients without PAH.43
Bosentan has been trialled in IPF, but patients with PAH were
excluded.44 In a small open-label trial of IV epoprostenol and sil-
denaﬁl, oxygenation was worsened by epoprostenol and improved
by sildenaﬁl.45 Another open-label study of sildenaﬁl in IPF showed
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resulted in improved haemodynamics in another small study.47
Overall, the use of vasodilators in IPF is not currently justiﬁed
outside of clinical trials. It is recommended that patients awaiting
lung transplantation for IPF have regular echocardiography to
monitor RV function in the event of developing PAH.
3.4. Other interstitial lung diseases
Interstitial lung disease may be idiopathic (the idiopathic
interstitial pneumonias, IIP) or secondary to other conditions such
as connective tissue diseases.
PAH associated with ILD may be a consequence of the hypoxia,
interstitial ﬁbrosis, vascular remodelling and hyperviscosity that
complicate these conditions as they advance. Additionally, and
especially in the case of secondary ILD, PAH may represent a sepa-
rate consequence of the underlying systemic process causing ILD.
Studies in IPF suggest that PAH risk is independent of lung function
impairment.7
3.5. Sarcoidosis
Prevalence estimates for PAH in sarcoidosis have ranged from 1–
28%.48 Most of these estimates have been based on echocardiog-
raphy, but echo ﬁndings seem to correlate acceptably with RHC in
sarcoidosis.49
Most patients listed for lung transplantation for sarcoidosis
have PAH on RHC.50 Risk factors may include lung function
impairment (especially total lung capacity), male gender, and
more severe changes on chest X-ray.48
Sarcoidosis can cause pulmonary hypertension in several ways.
PAH as a nonspeciﬁc consequence of progressive hypoxia and
ﬁbrosis associated with interstitial lung disease seems to account
for most cases,49,51,52 but not all. Several published cases describe
extrinsic compression of large vessels by mediastinal lymphade-
nopathy or mediastinal ﬁbrosis.53 Granulomatous vasculitis is
a common histopathological ﬁnding and seems to preferentially
involve veins.49,54
A subgroup of patients may respond to immunosuppressive
therapy in the absence of vasodilators: there are several reports of
success with corticosteroids.49,55–57 Corticosteroid responsiveness
may confound attempts to study the effects of pulmonary vasodi-
lators in sarcoidosis, as most of the study population will receive
concomitant immunosuppressants.
In a retrospective analysis of 22 patients with sarcoidosis-
associated PAH who were treated with vasodilator therapy,
improved haemodynamics and exercise capacity were seen.58 Most
patients had advanced pulmonary ﬁbrosis, and most also received
immunosuppressive therapy. In another retrospective study, long-
term haemodynamic improvements were seen with sildenaﬁl,
though exercise capacity was unchanged.59 Sustained haemody-
namic and functional improvements were seen in small cohorts
treated with bosentan,60-62 IV epoprostenol,63 and inhaled nitric
oxide.64
PAH caused by compression of large vessels has been success-
fully treated with stenting.65
3.6. Prognosis
The prognosis of sarcoidosis-associated PAH appears somewhat
better than IPAH, although this may depend on which pathophys-
iological mechanism is causing the patient’s PAH. In one cohort of
patients, 3 year transplant-free survival was 74%.58 Unsurprisingly
the presence of PAH worsens prognosis among patients awaiting
lung transplantation for sarcoidosis.Screening patients with sarcoidosis for PAH using 6MWD has
been advocated.9 This seems reasonable in patients with advanced
lung disease; in other cases the prevalence of PAH is still unknown,
and may not be high enough to justify screening in asymptomatic
patients.
3.7. Langerhans cell histiocytosis (LCH)
Severe PAH appears to be ubiquitous in advanced LCH: PAH was
present in 92% of cases of LCH referred for lung transplantation and
was moderate to severe in 73%.66 One study found severe PAH in all
tested patients.67 Severity of PAH appears to be independent of
lung function.67,68 Histology shows a proliferative vasculopathy
affecting muscular arteries, veins and venules; plexiform lesions
were not reported.67
A case of moderately severe LCH-associated PAH improved with
corticosteroid therapy and smoking cessation.69 Overall little has
been published about successful treatment of PAH in this condition.
3.8. Lymphangioleiomyomatosis (LAM)
A cross-sectional echocardiographic study in LAM reported
a prevalence of PAH of 7% at rest, rising to 47% with exercise,70 but
there is no published literature of treatment success.
4. Connective tissue diseases
The establishment of PAH registries has allowed estimates of the
prevalence of connective tissue disease-associated pulmonary
hypertension (PAH-CTD); in the United Kingdom it is estimated at
4.23 per million, with an incidence of 1.55/million/year.4 The esti-
mate from the French national registry is lower at 0.4/million/year.1
The strongest association is with scleroderma, which accounts for
76% of PAH-CTD in the French registry.1 PAH affects 3–16% of
patients with scleroderma,2,71–74 independent of the presence of
ILD.75 PAH is also common in systemic lupus erythematosus (SLE)1
and mixed connective tissue disease (MCTD).72,74,76
Reported risk factors include Raynaud’s syndrome,75,77–80
hypocomplementaemia,81 cryoglobulinaemia,81 anti-Ro,75 anti-
RNP 75,82 and anticardiolipin78,83–85 antibodies, and rheumatoid
factor positivity.75 In systemic sclerosis, anti-Scl 70 antibodies may
be associated with a lower risk of PAH.8
The similarity of the pathologic lesion in PAH-CTD and IPAH, the
female predominance among patients with IPAH, and the associa-
tion of IPAH with autoantibodies and autoimmune conditions86–88
has led to speculation that IPAH might be an autoimmune disease.
This would be supported by examples of patients who initially
present with ‘‘idiopathic’’ PAH, then proceed to develop other
features of a connective tissue disease; however opportunities to
observe this have until now been limited by the shortened life
expectancy of patients with PAH. This situation may change with
more widespread use of pulmonary vasodilator therapy. Observa-
tions of a therapeutic response to immunosuppressive therapy
alone add further weight to this hypothesis.89,90
4.1. Pathophysiology of PAH-CTD
Endothelial cells produce endothelin-1, nitric oxide (NO) and
prostacyclin (PGI, epoprostenol). There is substantial evidence
suggesting that endothelial cells are dysfunctional in PAH-CTD.
Expression of endothelial nitric oxide synthase (eNOS) is reduced
in PAH,91 and among patients with scleroderma expression of eNOS
is also reduced.92
Levels of endothelin-1, a potent vasoconstrictor, promoter of
ﬁbrosis and smooth muscle mitogen with a central role in IPAH
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higher levels are associated with increased risk of PAH.
Anti-endothelial cell antibodies (AECA) have been reported in
association with PAH in SSc,95 MCTD85,96 and SLE,97 and higher
AECA serum levels are associated with increased risk of PAH.95
AECA may be pathogenic: exposure to AECA caused healthy
endothelial cells to increase E-selectin expression96 and
endothelin-1 secretion.97
Anti-ﬁbrillarin antibodies are reported in association with PAH-
SSc and PAH-SLE.83,98 Anti-tissue plasminogen activator antibodies
are associatedwith increased risk of PAH in SSc,99 and are alsomore
common in IPAH.100 Anti-ﬁbrillin-1 antibodies are common in
scleroderma.101
4.2. Treatment of PAH-CTD
In general, treatment practices have been extrapolated from
IPAH. The prevalence of pulmonary veno-occlusive disease may be
increased in patients with PAH-CTD,102 so extra care is required to
exclude evidence of this condition when starting vasodilator
therapy.
4.2.1. Prostacyclin analogues
Patients with PAH-CTD treated with IV epoprostenol have
shown improvements in functional class, 6MWD, and haemody-
namics in short term open-label studies.103–105 Longer-term studies
of IV prostacyclin and inhaled iloprost have suggested clinical and
haemodynamic beneﬁts in PAH-CTD and SSc.106,107
In a post hoc analysis of a double-blind randomised trial of IV
treprostinil versus placebo, patients with PAH-CTD (50% sclero-
derma, 28% SLE, 22% MCTD) showed haemodynamic improve-
ments, a marginal increase in 6MWD, and no improvement in Borg
dyspnoea score.108 No beneﬁt was seen from beraprost in a short
term randomised trial.109
4.2.2. Endothelin-1 receptor antagonists
In cohort studies, long term treatment with the nonselective
endothelin-1 receptor antagonist bosentan improved exercise
capacity and RVSP,110 and was associated with 92% 48-week
survival.111
In a subgroup analysis of an open-label randomised trial of
sitaxsentan versus bosentan, patients with PAH-CTD had better 1-
year survival with sitaxsentan and were less likely to withdraw
from sitaxsentan than bosentan.112
4.2.3. Immunosuppression
There have been several case reports and case series describing
physiological and clinical responses of PAH-CTD to various forms of
immunosuppression alone.75,113–125
4.3. Prognosis of PAH-CTD
A review of hospital discharge records from Scotland found
a median survival of 5.9 years in males and 4.9 years in females.126
Pulmonary involvement is the leading cause of death in
scleroderma127 and MCTD.128 1-year survival in PAH-SSc is only
78%.4 Survival in PAH associated with polymyositis, SLE and MCTD
appears to be better with reported 3-year survival of 100%, 74% and
63% respectively.4
Negative prognostic factors reported in PAH-CTD include
sPAP> 60 mmHg, DLCO< 35% predicted, elevated mean right atrial
pressure, shorter time between diagnoses of CTD and PAH, and
presence of ILD.129,130 Favourable factors include younger age,
female sex, better WHO functional class, and higher mixed venous
oxygen saturation.45. Portopulmonary hypertension
Portopulmonary hypertension (PAH-PH) is deﬁned as pulmo-
nary arterial hypertension in the setting of portal hypertension.131
Prospective studies indicate 1–6% of portal hypertension is
complicated by PAH.132–134 Portal hypertension accounted for 10.4%
of secondary PAH in the French registry1; most patients were male,
though this probably reﬂects the overwhelming male predomi-
nance among cirrhotic patients, and there may in fact still be
a female preponderance.131,135 Other risk factors may include
autoimmune hepatitis135 and mutations in oestrogen signalling
pathways.136
PAH-PH is more commonly conﬁrmed using RHC than most
other forms of PAH, owing to its importance as a prognostic factor
in liver transplantation. Echocardiography again appears over-
sensitive, with reported PPV of 59–65%.133,137 A benign hyper-
dynamic circulatory state is common in liver disease and cannot be
distinguished from PAH-PH on echocardiographic grounds.
Nevertheless echocardiographic screening is advocated where liver
transplantation is being contemplated, provided diagnoses are
conﬁrmed by RHC.138
The pathogenesis of PAH-PH is unclear, and may involve endo-
thelial shear stress, or the effects of vasoconstrictors moving from
the portal to the pulmonary circulation.139 Endothelin-1 levels are
elevated in the pulmonary circulation of patients with PAH-PH140;
however they will often have a better haemodynamic proﬁle than
IPAH owing to elevated systemic prostacyclin and nitric oxide
levels that typify portal hypertension.141,142 This may render some
forms of vasodilator therapy less effective or even hazardous in
PAH-PH.143
Intravenous epoprostenol has been associated with haemody-
namic beneﬁts in short-term144 and long-term107 open-label
studies. A case series showing deterioration in portal hyperten-
sion with worsening splenomegaly after epoprostenol adminis-
tration has also been published.143
Patients with severe PAH-PH have shown improved functional
capacity and haemodynamics in two retrospective cohort studies of
long term bosentan treatment.145,146 Bosentan appeared to have
greater beneﬁcial effects than inhaled iloprost on symptoms, hae-
modynamics, and survival. There are case reports of successful use
of sildenaﬁl147 and combination therapy with iloprost, sildenaﬁl
and bosentan.148
The prognostic implications of PAH-PH are unclear. Some
retrospective studies have suggested a poor outcome,149 others
have not.132 Published estimates of 3-year survival range between
38–89%131,149,150; presence and severity of cirrhosis emerged as
negative prognostic factors.131
6. Hereditary haemorrhagic telangiectasia (HHT)
HHT is a common autosomal dominant disorder where muta-
tions in genes of the TGFb receptor family lead to mucocutaneous
telangiectasia and visceral arteriovenous malformations. Individ-
uals with HHT may develop PAH as a result of the high-output
circulatory state associated with multiple arteriovenous malfor-
mations,151 or as an isolated phenomenon clinically similar to IPAH.
The latter presentation is strongly associated with mutations in the
gene for activin receptor-like kinase-1 (ACVRL1).152,153
True PAH is probably a rare complication of HHT.154 An echo-
cardiographic screening study found evidence of PAH in 12% of
patients with HHT; however only one patient underwent conﬁr-
matory RHC, so the signiﬁcance of this result is unclear. It seems
likely that where HHT is accompanied by signiﬁcant arteriovenous
shunt, pulmonary arterial pressures will be mildly elevated on
echocardiography due to hyperdynamic circulatory state.
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PAH. Cases of successful treatment with long term IV prostacy-
clin155 and bosentan156 have been reported.7. Stimulants and appetite suppressants
In the 1970s, a European epidemic of PAH associated with use of
the amphetamine-like appetite suppressant aminorex led to the
withdrawal of that agent.157 A decade later, the serotonin reuptake
inhibitor fenﬂuramine was also implicated in causing PAH.158 This
was conﬁrmed in a case-control study which found an odds ratio of
23.1 among patients using fenﬂuramine derivatives for over 3
months.159 Fenﬂuramine was withdrawn from sale in 1997. Path-
ogenesis of anorexigen-associated PAH is probably through eleva-
tion of circulating levels of serotonin, a pulmonary vasoconstrictor
and smooth muscle mitogen. Use of other stimulants has also been
associated with risk of PAH, including amphetamine, metham-
phetamine and cocaine.160
Anorexigen-associated PAH accounted for 9.5% of cases of RHC-
conﬁrmed PAH in a national French registry.177% of cases were due
to fenﬂuramine derivatives. The role of echocardiographic
screening for PAH and valvular disease in individuals exposed to
anorexigens is unclear. One published study found evidence of PAH
in 6.7% of screened women, though conﬁrmatory RHC was not
performed.161
Once established, anorexigen-associated PAH appears to follow
a similar clinical course to IPAH,162 leading some commentators to
suggest that anorexigens precipitate rather than cause PAH.162 This
is supported by the detection of BMPR2 mutations in 9–22.5% of
patients with anorexigen-associated PAH.162,1638. Human immunodeﬁciency virus (HIV) infection
HIV infection is a moderately strong risk factor for PAH; about
0.5% of HIV-positive individuals have PAH.164 HIV infection
accounted for 6.2% of cases of secondary PAH in the French registry
data reported by Humbert et al.1 Most patients were male. Patho-
logical studies show plexiform arterial lesions, as in IPAH.165
HIV infection is associated with immune deﬁciency and dysre-
gulation, and HIV-infected lymphocytes and macrophages secrete
inﬂammatory cytokines. Additionally, several connections have been
made between viral antigens and pathogenesis of PAH. The gp120
viral envelope protein stimulates endothelial cells and macrophages
to secrete endothelin-1.166 Nef antigen is found in endothelial cells
from HIV-positive patients,167 and seems to induce those cells to
proliferate.167 Macaques infected with a Nef-expressing strain of
simian immunodeﬁciency virus develop plexiform lesions.167 The tat
viral protein also activates endothelial cells, stimulates angiogenesis,
and suppresses BMPR2 gene expression in vitro.168
A genotyping study of HIV-positive patients with PAH found an
increased frequency of HLA-eDR6 and HLA-DR52 alleles,169
a ﬁnding also noted in diffuse inﬁltrative lymphocytosis
syndrome (DILS), an uncommon immune response to HIV infection
which bears some similarities to Sjo¨gren syndrome.
There is little published literature speciﬁc to the treatment of
HIV-associated PAH (PAH-HIV). A cohort study of bosentan showed
improvements in 6MWD, haemodynamics and functional class at 4
months that were maintained beyond 12 months of followup.170
PAH-HIV appears to run a more aggressive course than IPAH,
with a 1 year survival of 51–73% andmedian survival of 1.3 years.171
PAH is the cause of death in 72% of patients with PAH-HIV.171 A CD4
count< 200 confers a worse prognosis, and highly active anti-
retroviral therapy may reduce the incidence of PAH-HIV by main-
taining immunocompetence.172,1739. Screening
The role of screening is unresolved for many of the conditions
discussed above. Criteria that must be satisﬁed in order to justify
a screening programme include evidence that early detection
improves outcome, existence of a reasonably accurate screening
test, and a risk of the condition that is high enough to compen-
sate for the expense and personal risk associated with screening
procedures.174 Currently screening for secondary PAH is speciﬁ-
cally advocated in scleroderma,175,176 congenital heart disease
with left-to-right shunt, and portal hypertension where liver
transplantation is being considered.176,177 A recent consensus
statement advocates screening with echocardiography in any
disease where PAH is a known complication, proceeding to RHC
for patients with TR velocity >¼ 2.8 m/s and normal right atrial
pressure.176
Screening relies on a clear deﬁnition of the disorder of interest.
This is complicated in PAH: ﬁrst, by the increase in normal
pulmonary artery pressures with age,178 and second, by the rec-
ognised phenomenon of ‘‘proportionate’’ mild or moderate
pulmonary hypertension in association with many cardiorespira-
tory disorders.6 This ‘‘proportionate’’ pulmonary hypertension may
not adversely affect prognosis, although few of the prognostic
studies we have reviewed have stratiﬁed for degree of pulmonary
hypertension. The point where proportionate pressures become
disproportionate has not been deﬁned.6
Owing to the risks and resource limitations associatedwith right
heart catheterisation, echocardiography has been the test most
commonly used to screen for PAH. The problem of false positives in
echocardiographic diagnosis of PAH is well recognised.2,3,19,133,137
This has led to interest in other screening modalities. Several
studies have examined exhaled nitric oxide (ENO) as a screening
test. Three groups have reported that ENO levels are elevated
overall in scleroderma compared with healthy controls, but low-
ered in PAH-SSc.179–181 An inverse correlation between ENO and
PAP was also reported.180,181 A small study of IPAH and anorexigen-
associated PAH found that ENO levels normalised after 3 months of
bosentan therapy.182
Computed tomography/magnetic resonance pulmonary angi-
ography is also promising, with pulmonary artery distensibility
showing high sensitivity and speciﬁcity for PAH.183,184
The vasoactive hormone brain natriuretic peptide (BNP) and its
N-terminal fragment (N-terminal pro-BNP) correlate with haemo-
dynamic parameters and functional status in PAH,185–189 and may
predict prognosis43,185,188 and response to therapy190 in at least
some forms of secondary PAH. The role of BNP or NT-proBNP as
a screening test for PAH, alone or in combination with echocardi-
ography, warrants further research.10. Conclusion
Pulmonary hypertension is a serious and increasingly recog-
nised complication of many respiratory and systemic diseases.
Diagnosis is difﬁcult, as echocardiography, while sensitive, is
a poorly speciﬁc test for PAH. To avoid unnecessarily exposing
patients to the risks of RHC, the combination of echocardiography
with other noninvasive screening tests should continue to be
explored. BNP, ENO and CT/MR pulmonary angiography each show
signs of promise in this regard.
Development of PAH is generally associated with poor prog-
nosis, and secondary PAH is the leading cause of death in some of
the conditions reviewed. For most of the available treatment
modalities, evidence of efﬁcacy is minimal or nonexistent, though
this situation is gradually improving.
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Educational questions
Answer the following questions:
1. In pulmonary arterial hypertension secondary to chronic
obstructive pulmonary disease (COPD), which one of the
following statements is true?
a. Moderate or severe PAH is a very common ﬁnding in end
stage COPD
b. While large randomised trials are lacking, the balance of
available evidence suggests that pulmonary vasodilators
are beneﬁcial
c. For a patient with COPD and an FEV1 of 65% predicted,
a DLCO of 30% predicted is disproportionately low and
suggests the presence of PAH
d. All patients with severe COPD should be screened for
pulmonary hypertension with annual transthoracic
echocardiography.
2. The most widely recommended noninvasive screening test for
PAH in systemic sclerosis is:
a. 6 minute walk test looking at desaturation, dyspnoea, and
distance walked
b. DLCO
c. Brain natriuretic peptide
d. Transthoracic echocardiography
3. In sarcoidosis, which one of the following statements is true?
a. PAH is a very common complication in end stage pulmonary
sarcoidosis
b. There is no relationship between severity of interstitial lung
disease and risk of PAH.
c. Most cases are due to compression of pulmonary vessels by
intrathoracic lymphadenopathy and mediastinal ﬁbrosis
d. While immunosuppression is often effective for sarcoidosis,
it is not effective in treating associated PAH
4. In PAH associated with connective tissue disorders, which one
of the following statements is true?
a. Among patients with systemic sclerosis, PAH is now the
leading cause of death.
b. Mixed connective tissue disorder is the CTD accounting for
the greatest number of cases of PAH.
c. The presence of antibodies to Scl-70 indicates increased risk
of PAH.
d. Female sex is associated with a worse prognosis.
5. In PAH associated with HIV infection, which one of the
following statements is true?
a. The gag viral protein may play a role in pathogenesis by
suppressing expression of the BMPR2 gene product.
b. Prognosis correlates with CD4 count.
c. More of this patient group will die from opportunistic
infections than from PAH.d. In countries where highly active antiretroviral therapy
(HAART) is widely available, PAH is now the leading cause
of death among HIV-positive individuals.References
1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.
Pulmonary arterial hypertension in france: results from a national registry. Am
J Respir Crit Care Med 2006;173:1023–30.
2. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early
detection of pulmonary arterial hypertension in systemic sclerosis: a French
nationwide prospective multicenter study. Arthritis Rheum 2005;52:
3792–800.
3. Penning S, Robinson KD, Major CA, Garite TJ. A comparison of echocardiog-
raphy and pulmonary artery catheterization for evaluation of pulmonary
artery pressures in pregnant patients with suspected pulmonary hyperten-
sion. Am J Obstet Gynecol 2001;184:1568–70.
4. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, et al. Connective
tissue disease-associated pulmonary arterial hypertension in the modern
treatment era. Am J Respir Crit Care Med 2009;179:151–7.
5. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al.
Clinical classiﬁcation of pulmonary hypertension. J Am Coll Cardiol
2004;43:5S–12S.
6. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al.
Interstitial lung disease guideline: the British thoracic society in collaboration
with the thoracic society of Australia and New Zealand and the Irish thoracic
society. Thorax 2008;63(Suppl. 5):v1–58.
7. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hyper-
tension and pulmonary function testing in idiopathic pulmonary ﬁbrosis.
Chest 2007;131:657–63.
8. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in
patients with systemic sclerosis and limited cutaneous involvement. Arthritis
Rheum 2003;48:516–22.
9. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in
sarcoidosis. Eur Respir J 2008;32:296–302.
10. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status
assessment in sarcoidosis. Chest 2007;132:207–13.
11. Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, et al.
Hemodynamic and functional assessment of patients with sickle cell disease
and pulmonary hypertension. Am J Respir Crit Care Med 2007;175:1272–9.
12. Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EM, Leme Jr CA,
Marques-Neto JF, et al. Six-minute walk test for the evaluation of pulmonary
disease severity in scleroderma patients. Chest 2007;131:217–22.
13. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk
test in interstitial lung disease and pulmonary hypertension in scleroderma.
J Rheumatol 2009;36:330–6.
14. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al.
Pulmonary hemodynamics in advanced copd candidates for lung volume
reduction surgery or lung transplantation. Chest 2005;127:1531–6.
15. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe
pulmonary hypertension and chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2005;172:189–94.
16. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in copd. Eur
Respir J 2008;32:1371–85.
17. Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe
pulmonary hypertension associated with copd. Ann Transplant 2000;5:8–12.
18. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,
Charpentier C, et al. Prognostic factors in copd patients receiving long-term
oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:
1193–8.
19. Arcasoy SM, Christie JD, Ferrari VA, Sutton MSJ, Zisman DA, Blumenthal NP,
et al. Echocardiographic assessment of pulmonary hypertension in
patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:
735–40.
20. Carratu P, Scoditti C, Maniscalco M, Seccia TM, Gioia GD, Gadaleta F, et al.
Exhaled and arterial levels of endothelin-1 are increased and correlate with
pulmonary systolic pressure in copd with pulmonary hypertension. BMC Pulm
Med 2008;8:20.
21. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of
chronic obstructive lung disease by nifedipine: an 18-month haemodynamic
study. Eur Respir J 1988;1:716–20.
22. Blanco I, Gimeno E, Munoz PA, Gomez FP, Pizarro S, Gistau C, et al. Sildenaﬁl in
pulmonary hypertension associated with copd [abstract]. Am J Respir Crit Care
Med 2009;179:A1046.
23. Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a copd
patient with severe pulmonary hypertension. Chest 2009;135:536–7.
24. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P,
et al. Controlled prospective randomised trial on the effects on pulmonary
haemodynamics of the ambulatory long term use of nitric oxide and oxygen in
patients with severe copd. Thorax 2003;58:289–93.
25. Cottin V, Khouatra C, Lazor R, Canu P, Cordier J- F. Pulmonary hypertension
therapy and copd: still many questions to be answered. Eur Respir J
2009;33:450–2. author reply 452–53.
P. Sexton, M.L. Wilsher / Respiratory Medicine CME 3 (2010) 1–9 726. Stolz D, Rasch H, Linka A, Valentino MD, Meyer A, Brutsche M, et al. A
randomised, controlled trial of bosentan in severe copd. Eur Respir J
2008;32:619–28.
27. Chapman TH, Wilde M, Sheth A, Madden BP. Sildenaﬁl therapy in secondary
pulmonary hypertension: is there beneﬁt in prolonged use? Vascul Pharmacol;
2009.
28. Hoeper MM. Treating pulmonary hypertension in copd: where do we start?
Eur Respir J 2008;32:541–2.
29. Arias MA, Garcia-Rio F, Alonso-Fernandez A, Martinez I, Villamor J. Pulmonary
hypertension in obstructive sleep apnoea: effects of continuous positive
airway pressure: a randomized, controlled cross-over study. Eur Heart J
2006;27:1106–13.
30. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial
hypertension in patients with sleep apnoea syndrome. Thorax 2000;55:934–9.
31. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary
hemodynamics in the obstructive sleep apnea syndrome. Results in 220
consecutive patients. Chest 1996;109:380–6.
32. Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J.
Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep
apnea patients. Chest 1989;96:729–37.
33. Niijima M, Kimura H, Edo H, Shinozaki T, Kang J, Masuyama S, et al. Mani-
festation of pulmonary hypertension during rem sleep in obstructive sleep
apnea syndrome. Am J Respir Crit Care Med 1999;159:1766–72.
34. Atwood CW, McCrory D, Garcia JGN, Abman SH, Ahearn GS, of Chest
Physicians AC. Pulmonary artery hypertension and sleep-disordered
breathing: Accp evidence-based clinical practice guidelines. Chest 2004;126:
72S–77S.
35. Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC. Nocturnal hypoxemia
is common in primary pulmonary hypertension. Chest 2001;120:894–9.
36. Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou JB.
Daytime pulmonary hypertension in patients with obstructive sleep apnea:
the effect of continuous positive airway pressure on pulmonary hemody-
namics. Respiration 2001;68:566–72.
37. Laks L, Lehrhaft B, Grunstein RR, Sullivan CE. Pulmonary hypertension in
obstructive sleep apnoea. Eur Respir J 1995;8:537–41.
38. Sajkov D, Wang T, Saunders NA, Bune AJ, Mcevoy RD. Continuous positive
airway pressure treatment improves pulmonary hemodynamics in patients
with obstructive sleep apnea. Am J Respir Crit Care Med 2002;165:152–8.
39. Ogawa A, Emori T, Sumita W, Watanabe A, Fujio H, Miyaji K, et al. Continuous
positive airway pressure ameliorated severe pulmonary hypertension asso-
ciated with obstructive sleep apnea. Acta Med Okayama 2006;60:191–5.
40. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and
outcomes of pulmonary arterial hypertension in advanced idiopathic
pulmonary ﬁbrosis. Chest 2006;129:746–52.
41. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA,
et al. Pulmonary hypertension in patients with idiopathic pulmonary ﬁbrosis.
Chest 2005;128:2393–9.
42. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Signif-
icance of pulmonary arterial pressure and diffusion capacity of the lung as
prognosticator in patients with idiopathic pulmonary ﬁbrosis. Chest
2007;131:650–6.
43. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as
prognostic indicators in idiopathic pulmonary ﬁbrosis. Respir Med
2009;103:180–6.
44. King E, Behr J, Brown K, du Bois M, Lancaster L, de Andrade A, et al. Build-1:
a randomized placebo-controlled trial of bosentan in idiopathic pulmonary
ﬁbrosis. Am J Respir Crit Care Med; 2008.
45. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H,
Weissmann N, et al. Sildenaﬁl for treatment of lung ﬁbrosis and pulmonary
hypertension: a randomised controlled trial. Lancet 2002;360:895–900.
46. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenaﬁl improves walk
distance in idiopathic pulmonary ﬁbrosis. Chest 2007;131:897–9.
47. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-
Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe
pulmonary hypertension secondary to lung ﬁbrosis. Am J Respir Crit Care Med
1999;160:600–7.
48. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, et al. Incidence of
pulmonary hypertension and its clinical relevance in patients with sarcoid-
osis. Chest 2006;129:1246–52.
49. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti JP, et al.
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemo-
dynamics and prognosis. Thorax 2006;61:68–74.
50. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in
advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J
2005;25:783–8.
51. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ.
Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic
study of 20 cases. Hum Pathol 2002;33:1037–43.
52. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive
clinical, radiographic, and functional characteristics of patients with
sarcoidosis-related pulmonary hypertension. Chest 2005;128:1483–9.
53. Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis
causing pulmonary hypertension in sarcoidosis. Chest 1980;78:888–91.
54. Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in
sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992;23:1216–23.55. Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in
sarcoidosis. Postgrad Med J 1982;58:282–5.
56. Mangla A, Fisher J, Libby DM, Saddekni S. Sarcoidosis, pulmonary hyperten-
sion, and acquired peripheral pulmonary artery stenosis. Cathet Cardiovasc
Diagn 1985;11:69–74.
57. Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated
pulmonary hypertension with corticosteroids. Chest 1990;97:500–2.
58. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin OA, Osei K, et al. Treat-
ment of sarcoidosis-associated pulmonary hypertension: a two-center expe-
rience. Chest; 2008.
59. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary
hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sil-
denaﬁl? J Heart Lung Transplant 2008;27:329–34.
60. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis
Res Ther 2007;9(Suppl 2):S8.
61. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated
pulmonary hypertension with bosentan. Respiration 2008;75:211–4.
62. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension:
treated with endothelin receptor blockade. Tex Heart Inst J 2005;32:405–10.
63. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoid-
osis-associated pulmonary hypertension: outcome with long-term epopros-
tenol treatment. Chest 2006;130:1481–8.
64. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vaso-
responsiveness of sarcoidosis-associated pulmonary hypertension. Chest
2001;120:866–72.
65. Hamilton-Craig CR, Slaughter R, McNeil K, Kermeen F, Walters DL. Improve-
ment after angioplasty and stenting of pulmonary arteries due to sarcoid
mediastinal ﬁbrosis-case report. Heart Lung Circ; 2008.
66. Dauriat G, Mal H, Thabut G, Mornex JF, Bertocchi M, Tronc F, et al. Lung
transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter
analysis. Transplantation 2006;81:746–50.
67. Fartoukh M, Humbert M, Capron F, Maitre S, Parent F, Le Gall C, et al. Severe
pulmonary hypertension in histiocytosis x. Am J Respir Crit Care Med
2000;161:216–23.
68. Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocy-
tosis x is associated with severe pulmonary hypertension. Chest
1997;111:1142–4.
69. Benyounes B, Crestani B, Couvelard A, Vissuzaine C, Aubier M. Steroid-
responsive pulmonary hypertension in a patient with langerhans’ cell gran-
ulomatosis (histiocytosis x). Chest 1996;110:284–6.
70. Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW,
Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echo-
cardiographic study. Chest 2007;132:1573–8.
71. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in
systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:
989–93.
72. Kondo H. Autoimmune aspects of pulmonary hypertension in collagen
vascular diseases. Intern Med 2003;42:1163–4.
73. Mukerjee D, George DS, Coleiro B, Knight C, Denton CP, Davar J, et al. Preva-
lence and outcome in systemic sclerosis associated pulmonary arterial
hypertension: application of a registry approach. Ann Rheum Dis
2003;62:1088–93.
74. Wigley FM, Lima JAC, Mayes M, McLain D, Chapin JL, Ward-Able C. The
prevalence of undiagnosed pulmonary arterial hypertension in subjects with
connective tissue disease at the secondary health care level of community-
based rheumatologists (the uncover study). Arthritis Rheum 2005;52:2125–32.
75. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M,
et al. Prevalence and characteristics of moderate to severe pulmonary
hypertension in systemic sclerosis with and without interstitial lung disease.
J Rheumatol 2007;34:1005–11.
76. Prakash UB. Respiratory complications in mixed connective tissue disease.
Clinics in Chest Medicine 1998;19:733–46. ix.
77. Chen CH, Chen HA, Wang HP, Liao HT, Chou CT, Huang DF. Pulmonary arterial
hypertension in autoimmune diseases: an analysis of 19 cases from a medical
center in northern Taiwan. J Microbiol Immunol Infect 2006;39:162–8.
78. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus:
clinical association and survival in 18 patients. J Rheumatol 1999;26:1923–9.
79. Shen JY, Chen SL, Wu YX, Tao RQ, Gu YY, Bao CD, et al. Pulmonary hyper-
tension in systemic lupus erythematosus. Rheumatology International
1999;18:147–51.
80. Shen M, Zhang F, Zhang X. Pulmonary hypertension in primary biliary
cirrhosis: a prospective study in 178 patients. Scand J Gastroenterol
2009;44:219–23.
81. Vassiliou VA, Moyssakis I, Boki KA, Moutsopoulos HM. Is the heart affected in
primary sjogren’s syndrome? An echocardiographic study. Clin Exp Rheumatol
2008;26:109–12.
82. Kasukawa R, Nishimaki T, Takagi T, Miyawaki S, Yokohari R, Tsunematsu T.
Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty
patients in multi-institutional study. Clin Rheumatol 1990;9:56–62.
83. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GR.
Pulmonary hypertension in systemic lupus erythematosus: a report of three
cases. J Rheumatol 1986;13:416–20.
84. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M, et al.
Immunological analysis of pulmonary hypertension in connective tissue
diseases. J Rheumatol 1999;26:2357–62.
P. Sexton, M.L. Wilsher / Respiratory Medicine CME 3 (2010) 1–9885. Vegh J, Szodoray P, Kappelmayer J, Csipo I, Udvardy M, Lakos G, et al. Clinical
and immunoserological characteristics of mixed connective tissue disease
associated with pulmonary arterial hypertension. Scand J Immunol
2006;64:69–76.
86. Morse JH, Antohi S, Kasturi K, Saito S, Fotino M, Humbert M, et al. Fine
speciﬁcity of anti-ﬁbrillin-1 autoantibodies in primary pulmonary hyperten-
sion syndrome. Scand J Immunol 2000;51:607–11.
87. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.
Primary pulmonary hypertension. A national prospective study. Ann Intern
Med 1987;107:216–23.
88. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear
antibodies in primary pulmonary hypertension. J Am Coll Cardiol
1986;8:1307–11.
89. Bellotto F, Chiavacci P, Laveder F, Angelini A, Thiene G, Marcolongo R. Effective
immunosuppressive therapy in a patient with primary pulmonary hyper-
tension. Thorax 1999;54:372–4.
90. Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, et al.
Prednisolone inhibits proliferation of cultured pulmonary artery smooth
muscle cells of patients with idiopathic pulmonary arterial hypertension.
Circulation 2005;112:1806–12.
91. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in
the lungs of patients with pulmonary hypertension. N Engl J Med
1995;333:214–21.
92. Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R, et al. Differential
expression of nitric oxide by dermal microvascular endothelial cells from
patients with scleroderma. Vasc Med 2000;5:147–58.
93. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, et al. Plasma
endothelin-1 levels, pulmonary hypertension, and lung ﬁbrosis in patients
with systemic sclerosis. Am J Med 1995;99:255–60.
94. Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M. Effect of
total-body cold exposure on plasma concentrations of von willebrand
factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus
patients with or without raynaud’s phenomenon. Acta Haematologica 1992;88:
189–93.
95. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in
scleroderma correlate with severe digital ischemia and pulmonary arterial
hypertension. J Rheumatol 1998;25:462–6.
96. Bodolay E, Csipo I, Gal I, Sipka S, Gyimesi E, Szekanecz Z, et al. Anti-endothelial
cell antibodies in mixed connective tissue disease: frequency and association
with clinical symptoms. Clin Exp Rheumatol 2004;22:409–15.
97. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1
release from cultured endothelial cells induced by sera from patients with
systemic lupus erythematosus. Ann Rheum Dis 1995;54:361–5.
98. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-ﬁbrillarin antibodies in
systemic sclerosis. Rheumatology (Oxford, England) 2001;40:1157–62.
99. Fritzler MJ, Hart DA, Wilson D, Garcia-De La Torre I, Salazar-Paramo M, Vaz-
quez-Del Mercado M, et al. Antibodies to ﬁbrin bound tissue type plasmin-
ogen activator in systemic sclerosis. J Rheumatol 1995;22:1688–93.
100. Morse JH, Barst RJ, Fotino M, Zhang Y, Flaster E, Gharavi AE, et al. Primary
pulmonary hypertension, tissue plasminogen activator antibodies, and hla-
dq7. Am J Respir Crit Care Med 1997;155:274–8.
101. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, et al. Autoantibodies to
the extracellular matrix microﬁbrillar protein, ﬁbrillin-1, in patients with
scleroderma and other connective tissue diseases. J Immunol 1999;163:1066–72.
102. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al.
Fibrous remodeling of the pulmonary venous system in pulmonary arterial
hypertension associated with connective tissue diseases. Hum Pathol
2007;38:893–902.
103. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al.
Continuous intravenous epoprostenol for pulmonary hypertension due to the
scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern
Med 2000;132:425–34.
104. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Sitbon O, Simonneau G. Treat-
ment of severe pulmonary hypertension secondary to connective tissue
diseases with continuous iv epoprostenol (prostacyclin). Chest 1998;114:80S–
82S.
105. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for
treatment of pulmonary hypertension in patients with systemic lupus
erythematosus. Chest 2000;117:14–8.
106. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S, et al. Aero-
solized iloprost in crest syndrome related pulmonary hypertension. J Rheu-
matol 2001;28:2252–6.
107. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate
use of continuous prostacyclin in the management of secondary pulmonary
hypertension: a case series. Ann Intern Med 1999;130:740–3.
108. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al. Treprostinil,
a prostacyclin analogue, in pulmonary arterial hypertension associated with
connective tissue disease. Chest 2004;126:420–7.
109. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects
of beraprost sodium, an oral prostacyclin analogue, in patients with pulmo-
nary arterial hypertension: a randomized, double-blind, placebo-controlled
trial. J Am Coll Cardiol 2002;39:1496–502.
110. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, et al. Bosentan
therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J
Clin Invest 2006;36(Suppl. 3):49–53.111. Denton CP, Pope JE, Peter H-H, Gabrielli A, Boonstra A, van den Hoogen FHJ,
et al. Long-term effects of bosentan on quality of life, survival, safety and
tolerability in pulmonary arterial hypertension related to connective tissue
diseases. Ann Rheum Dis 2008;67:1222–8.
112. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, et al. Sitaxsentan
for the treatment of pulmonary arterial hypertension: a 1-year, prospective,
open-label observation of outcome and survival. Chest 2008;134:775–82.
113. Castro GWR, Appenzeller S, Bertolo MB, Costallat LTL. Isolated pulmonary
hypertension secondary to rheumatoid arthritis. Clin Rheumatol 2006;25:
901–3.
114. Ribeiro JM, Lucas M, Victorino RM. Remission of precapillary pulmonary
hypertension in systemic lupus erythematosus. J R Soc Med 2001;94:32–3.
115. Pines A, Kaplinsky N, Goldhammer E, Olchovsky D, Frankl O. Corticosteroid
responsive pulmonary hypertension in systemic lupus erythematosus. Clin
Rheumatol 1982;1:301–4.
116. Groen H, Bootsma H, Postma DS, Kallenberg CG. Primary pulmonary hyper-
tension in a patient with systemic lupus erythematosus: partial improvement
with cyclophosphamide. J Rheumatol 1993;20:1055–7.
117. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary
hypertension in systemic lupus erythematosus: evaluation of clinical charac-
teristics and response to immunosuppressive treatment. J Rheumatol 2002;29:
282–7.
118. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al. Immuno-
suppressive therapy in lupus- and mixed connective tissue disease-associated
pulmonary arterial hypertension: a retrospective analysis of twenty-three
cases. Arthritis Rheum 2008;58:521–31.
119. Johnson SR, Gladman DD, Urowitz MB, Iban˜ez D, Granton JT. Pulmonary
hypertension in systemic lupus. Lupus 2004;13:506–9.
120. Dahl M, Chalmers A, Wade J, Calverley D, Munt B. Ten year survival of a patient
with advanced pulmonary hypertension and mixed connective tissue disease
treated with immunosuppressive therapy. J Rheumatol 1992;19:1807–9.
121. Ferri C, Emdin M, Storino FA, Giuggioli D, Longombardo G, Greco F, et al.
Isolated pulmonary hypertension in diffuse cutaneous systemic sclerosis
successfully treated with long-term plasma exchange. Scand J Rheumatol
2000;29:198–200.
122. Gonzalez-Lopez L, Cardona-Mun˜oz EG, Celis A, la Torre IG-d Orozco-Barocio G,
Salazar-Paramo M, Garcia-Gonzalez C, et al. Therapy with intermittent pulse
cyclophosphamide for pulmonary hypertension associated with systemic
lupus erythematosus. Lupus 2004;13:105–12.
123. Nakagawa N, Osanai S, Ide H, Nishigaki Y, Takahashi S, Nakano H, et al. Severe
pulmonary hypertension associated with primary sjogren’s syndrome. Intern
Med 2003;42:1248–52.
124. Zhang X, Zeng X. Severe pulmonary hypertension in pediatric primary sjogren
syndrome: a case report. J Clin Rheumatol 2007;13:276–7.
125. Tatsukawa H, Nagano S, Umeno Y, Oribe M. A case of primary sjogren’s
syndrome with severe pulmonary hypertension and glomerular damage.
Ryumachi 2003;43:564–8.
126. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemio-
logical study of pulmonary arterial hypertension. Eur Respir J 2007;30:104–9.
127. Arroliga AC, Podell DN, Matthay RA. Pulmonary manifestations of sclero-
derma. J Thorac Imaging 1992;7:30–45.
128. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-
term outcome in mixed connective tissue disease: longitudinal clinical and
serologic ﬁndings. Arthritis Rheum 1999;42:899–909.
129. Johnson SR, Swinton JR, Granton JT. Prognostic factors for survival in sclero-
derma associated pulmonary arterial hypertension. J Rheumatol 2008;35:
1584–90.
130. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin LF, et al. Is
pulmonary arterial hypertension really a late complication of systemic scle-
rosis? Chest; 2009.
131. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al. Porto-
pulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care
Med 2008;178:637–43.
132. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al.
Frequency and clinical implications of increased pulmonary artery pressures
in liver transplant patients. Mayo Clin Proc 1996;71:543–51.
133. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diag-
nosis of portopulmonary hypertension in candidates for liver transplantation:
a prospective study. Hepatology 2003;37:401–9.
134. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension
complicating portal hypertension: prevalence and relation to splanchnic
hemodynamics. Gastroenterology 1991;100:520–8.
135. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, et al.
Clinical risk factors for portopulmonary hypertension. Hepatology
2008;48:196–203.
136. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al. Genetic
risk factors for portopulmonary hypertension in patients with advanced liver
disease. Am J Respir Crit Care Med 2009;179:835–42.
137. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary
hypertension: results from a 10-year screening algorithm. Hepatology
2006;44:1502–10.
138. Murray KF, Carithers RL, AASL D. Aasld practice guidelines: evaluation of the
patient for liver transplantation. Hepatology 2005;41:1407–32.
139. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and
hepatopulmonary syndrome. Lancet 2004;363:1461–8.
P. Sexton, M.L. Wilsher / Respiratory Medicine CME 3 (2010) 1–9 9140. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Porto-
pulmonary hypertension in decompensated cirrhosis with refractory ascites.
Gut 2003;52:1355–62.
141. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic
circulation in patients with cirrhosis: direct measurement of nitric oxide levels
in hepatic and portal veins. J Hepatol 1997;26:75–80.
142. Sitzmann JV, Campbell K, Wu Y, Clair CS. Prostacyclin production in acute,
chronic, and long-term experimental portal hypertension. Surgery
1994;115:290–4.
143. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive spleno-
megaly after epoprostenol therapy in portopulmonary hypertension. Liver
Transpl Surg 1999;5:362–5.
144. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH.
Improvement in pulmonary hemodynamics during intravenous epoprostenol
(prostacyclin): a study of 15 patients with moderate to severe portopulmo-
nary hypertension. Hepatology 1999;30:641–8.
145. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al.
Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:
502–8.
146. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW,
et al. Experience with inhaled iloprost and bosentan in portopulmonary
hypertension. Eur Respir J 2007;30:1096–102.
147. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenaﬁl for porto-
pulmonary hypertension in a patient undergoing liver transplantation. Liver
Transpl 2004;10:945–50.
148. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety
and efﬁcacy of combined use of sildenaﬁl, bosentan, and iloprost before and
after liver transplantation in severe portopulmonary hypertension. Liver
Transpl 2008;14:287–91.
149. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE,
et al. Hemodynamics and survival of patients with portopulmonary hyper-
tension. Liver Transpl 2005;11:1107–11.
150. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of
european post-marketing surveillance of bosentan in pulmonary hyperten-
sion. Eur Respir J 2007;30:338–44.
151. Bhatia S, Morrison JF, Bower TC, McGoon MD. Pulmonary hypertension in the
setting of acquired systemic arteriovenous ﬁstulas. Mayo Clin Proc
2003;78:908–12.
152. Olivieri C, Lanzarini L, Pagella F, Semino L, Corno S, Valacca C, et al. Echocar-
diographic screening discloses increased values of pulmonary artery systolic
pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic
telangiectasia. Genet Med 2006;8:183–90.
153. Trembath R. Mutations in the tgf-beta type 1 receptor, alk1, in combined
primary pulmonary hypertension and hereditary haemorrhagic telangiectasia,
implies pathway speciﬁcity. J Heart Lung Transplant 2001;20:175.
154. Cottin V, Dupuis-Girod S, Lesca G, Cordier JF. Pulmonary vascular manifesta-
tions of hereditary hemorrhagic telangiectasia (rendu-osler disease). Respi-
ration 2007;74:361–78.
155. Minai OA, Rigelsky C, Eng C, Arroliga AC, Stoller JK. Long-term outcome in
a patient with pulmonary hypertension and hereditary hemorrhagic telangi-
ectasia. Chest 2007;131:984–7.
156. Bonderman D, Nowotny R, Skoro-Sajer N, Adlbrecht C, Lang IM. Bosentan
therapy for pulmonary arterial hypertension associated with hereditary hae-
morrhagic telangiectasia. Eur J Clin Invest 2006;36(Suppl. 3):71–2.
157. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from
the bedside to the bench. Am J Med Sci 2001;321:292–9.
158. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hyper-
tension and fenﬂuramine. Br Med J (Clin Res Ed) 1981;283:881–3.
159. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-
suppressant drugs and the risk of primary pulmonary hypertension. Inter-
national primary pulmonary hypertension study group. N Engl J Med
1996;335:609–16.
160. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with
idiopathic pulmonary arterial hypertension? Chest 2006;130:1657–63.
161. Bowen RL, Foreyt JP, Poston WS, Miller CC, Hyman D, Pendleton VR, et al.
Echocardiographic assessment of patients receiving long-term treatment with
anorexiant medications. Endocr Pract 1999;5:17–23.
162. Souza R, Humbert M, Sztrymf B, Jais X, Yaici A, Le Pavec J, et al. Pulmonary
arterial hypertension associated with fenﬂuramine exposure: report of 109
cases. Eur Respir J 2008;31:343–8.
163. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M, et al. Bmpr2
germline mutations in pulmonary hypertension associated with fenﬂuramine
derivatives. Eur Respir J 2002;20:518–23.
164. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Rafﬁ F, De Zuttere D, et al.
Prevalence of hiv-related pulmonary arterial hypertension in the current
antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–13.
165. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. Hiv-related pulmonary hyper-
tension: analytic review of 131 cases. Chest 2000;118:1133–41.166. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and
endothelin-1 secretion in primary human lung endothelial cells by hiv-1
gp120 proteins. Biochem Biophys Res Commun 2005;333:1107–15.
167. Marecki JC, Cool CD, Beckey VE, Voelkel NF, Flores SC. Hiv-1 nef protein is
present a the site of plexiform lesions in patients with hiv-related pulmonary
hypertension, and induces a program of altered endothelial cell growth and
survival in vitro. Proc Am Thoracic Soc 2006;3:A476.
168. Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. Hiv-1 tat represses tran-
scription of the bone morphogenic protein receptor-2 in u937 monocytic cells.
J Leukoc Biol 2006;79:192–201.
169. Morse JH, Barst RJ, Itescu S, Flaster ER, Sinha G, Zhang Y, et al. Primary
pulmonary hypertension in hiv infection: an outcome determined by partic-
ular hla class ii alleles. Am J Respir Crit Care Med 1996;153:1299–301.
170. Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, et al. Long-term effects
of bosentan in patients with hiv-associated pulmonary arterial hypertension.
Eur Respir J 2009;33:92–8.
171. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic
factors for survival in human immunodeﬁciency virus-associated pulmonary
arterial hypertension. Am J Respir Crit Care Med 2003;167:1433–9.
172. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly
active antiretroviral therapy in hiv-positive patients with cardiac involvement.
J Infect 2000;40:282–4.
173. Zuber J-P, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al.
Pulmonary arterial hypertension related to hiv infection: improved hemo-
dynamics and survival associated with antiretroviral therapy. Clin Infect Dis
2004;38:1178–85.
174. Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria for effective
screening: their application to multislice ct screening for pulmonary and
colorectal cancers. AJR Am J Roentgenol 2001;176:1357–62.
175. British Cardiac Society Guidelines and Medical Practice Committee. Recom-
mendations on the management of pulmonary hypertension in clinical
practice. Heart 2001;86(Suppl. 1):I1–13.
176. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus
statement on the management of pulmonary hypertension in clinical practice
in the UK and Ireland. Heart 2008;94(Suppl. 1):i1–41.
177. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al.
Diagnosis and differential assessment of pulmonary arterial hypertension. J
Am Coll Cardiol 2004;43:40S–47S.
178. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redﬁeld MM. Age-
associated increases in pulmonary artery systolic pressure in the general
population. Circulation; 2009.
179. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric
oxide in the exhaled air of patients with systemic sclerosis with pulmonary
hypertension. Thorax 1997;52:1051–5.
180. Malerba M, Radaeli A, Ragnoli B, Airo’ P, Corradi M, Ponticiello A, et al. Exhaled
nitric oxide levels in systemic sclerosis with and without pulmonary
involvement. Chest 2007;132:575–80.
181. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, et al.
Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement
and pulmonary hypertension. J Rheumatol 2000;27:1693–8.
182. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT.
Decreased exhaled nitric oxide in pulmonary arterial hypertension: response
to bosentan therapy. Am J Respir Crit Care Med 2005;172:352–7.
183. Bogren HG, Klipstein RH, Mohiaddin RH, Firmin DN, Underwood SR, Rees RS,
et al. Pulmonary artery distensibility and blood ﬂow patterns: a magnetic
resonance study of normal subjects and of patients with pulmonary arterial
hypertension. Am Heart J 1989;118:990–9.
184. Revel MP, Faivre JB, Remy-Jardin M, Delannoy-Deken V, Duhamel A, Remy J.
Pulmonary hypertension: Ecg-gated 64-section ct angiographic evaluation of
new functional parameters as diagnostic criteria. Radiology 2009;250:558–66.
185. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic
peptide levels in managing pediatric patients with pulmonary arterial
hypertension. Chest 2009;135:745–51.
186. Ciurzynski M, Bienias P, Lichodziejewska B, Kurnicka K, Szewczyk A, Glinska-
Wielochowska M, et al. Non-invasive diagnostic and functional evaluation of
cardiac involvement in patients with systemic sclerosis. Clin Rheumatol
2008;27:991–7.
187. Lammers AE, Hislop AA, Haworth SG. Prognostic value of b-type natriuretic
peptide in childrenwith pulmonary hypertension. Int J Cardiol 2009;135:21–6.
188. Leuchte HH, El NounouM, Tuerpe JC, Hartmann B, Baumgartner RA, VogeserM,
et al. N-terminal pro-brain natriuretic peptide and renal insufﬁciency as
predictors of mortality in pulmonary hypertension. Chest 2007;131:402–9.
189. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J.
Characterization of brain natriuretic peptide in long-term follow-up of
pulmonary arterial hypertension. Chest 2005;128:2368–74.
190. Simeoni S, Lippi G, Puccetti A, Montagnana M, Tinazzi E, Prati D, et al. N-
terminal pro-bnp in sclerodermic patients on bosentan therapy for pah.
Rheumatol Int 2008;28:657–60.
